APA (7th ed.) Citation

S, L., M, H., J, C., G, S., S, K., M, C., . . . BT, G. (2025). Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: A phase 1b/2a trial. Nature communications, 16(1), 2846. https://doi.org/10.1038/s41467-025-58179-6

Chicago Style (17th ed.) Citation

S, Loges, et al. "Bemcentinib as Monotherapy and in Combination with Low-dose Cytarabine in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy: A Phase 1b/2a Trial." Nature Communications 16, no. 1 (2025): 2846. https://doi.org/10.1038/s41467-025-58179-6.

MLA (9th ed.) Citation

S, Loges, et al. "Bemcentinib as Monotherapy and in Combination with Low-dose Cytarabine in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy: A Phase 1b/2a Trial." Nature Communications, vol. 16, no. 1, 2025, p. 2846, https://doi.org/10.1038/s41467-025-58179-6.